200 related articles for article (PubMed ID: 17949824)
1. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression.
Motta M; Imbesi R; Di Rosa M; Stivala F; Malaguarnera L
Immunol Lett; 2007 Nov; 114(1):46-51. PubMed ID: 17949824
[TBL] [Abstract][Full Text] [Related]
2. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia.
Di Rosa M; Dell'Ombra N; Zambito AM; Malaguarnera M; Nicoletti F; Malaguarnera L
Eur J Neurosci; 2006 May; 23(10):2648-56. PubMed ID: 16817867
[TBL] [Abstract][Full Text] [Related]
3. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.
Rota E; Bellone G; Rocca P; Bergamasco B; Emanuelli G; Ferrero P
Neurol Sci; 2006 Apr; 27(1):33-9. PubMed ID: 16688597
[TBL] [Abstract][Full Text] [Related]
4. Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer's disease.
Rodríguez-Rodríguez E; Sánchez-Juan P; Mateo I; Llorca J; Infante J; García-Gorostiaga I; Berciano J; Combarros O
Acta Neurol Scand; 2007 Dec; 116(6):409-12. PubMed ID: 17986101
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune aberrations in Alzheimer's disease patients.
Bonotis K; Krikki E; Holeva V; Aggouridaki C; Costa V; Baloyannis S
J Neuroimmunol; 2008 Jan; 193(1-2):183-7. PubMed ID: 18037502
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease.
Mocali A; Cedrola S; Della Malva N; Bontempelli M; Mitidieri VA; Bavazzano A; Comolli R; Paoletti F; La Porta CA
Exp Gerontol; 2004 Oct; 39(10):1555-61. PubMed ID: 15501026
[TBL] [Abstract][Full Text] [Related]
7. Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?
Richartz E; Stransky E; Batra A; Simon P; Lewczuk P; Buchkremer G; Bartels M; Schott K
J Psychiatr Res; 2005 Sep; 39(5):535-43. PubMed ID: 15992563
[TBL] [Abstract][Full Text] [Related]
8. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Immunol Lett; 2008 May; 117(2):198-202. PubMed ID: 18367253
[TBL] [Abstract][Full Text] [Related]
9. HCV infection in haemodialysed patients: a role for serum IL-10 and TGF-beta1 in liver damage?
Burra P; Masier A; Morisco F; Di Leo V; Zorzi M; Senzolo M; Marchini F; Guido M; Canova D; Floreani A; Burroughs AK
Dig Liver Dis; 2008 Oct; 40(10):827-33. PubMed ID: 18372225
[TBL] [Abstract][Full Text] [Related]
10. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients.
Reale M; Iarlori C; Gambi F; Feliciani C; Isabella L; Gambi D
Neuropharmacology; 2006 Apr; 50(5):606-13. PubMed ID: 16445950
[TBL] [Abstract][Full Text] [Related]
11. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease.
Baranowska-Bik A; Bik W; Wolinska-Witort E; Martynska L; Chmielowska M; Barcikowska M; Baranowska B
Neuro Endocrinol Lett; 2008 Feb; 29(1):75-9. PubMed ID: 18283248
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment.
Bossù P; Ciaramella A; Salani F; Bizzoni F; Varsi E; Di Iulio F; Giubilei F; Gianni W; Trequattrini A; Moro ML; Bernardini S; Caltagirone C; Spalletta G
Brain Behav Immun; 2008 May; 22(4):487-92. PubMed ID: 17988833
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.
Lindberg C; Chromek M; Ahrengart L; Brauner A; Schultzberg M; Garlind A
Neurochem Int; 2005 Jun; 46(7):551-7. PubMed ID: 15843049
[TBL] [Abstract][Full Text] [Related]
14. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
[TBL] [Abstract][Full Text] [Related]
15. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients.
Speciale L; Calabrese E; Saresella M; Tinelli C; Mariani C; Sanvito L; Longhi R; Ferrante P
Neurobiol Aging; 2007 Aug; 28(8):1163-9. PubMed ID: 16814429
[TBL] [Abstract][Full Text] [Related]
17. Cytokines in Alzheimer's disease and vascular dementia.
Angelopoulos P; Agouridaki H; Vaiopoulos H; Siskou E; Doutsou K; Costa V; Baloyiannis SI
Int J Neurosci; 2008 Dec; 118(12):1659-72. PubMed ID: 18937113
[TBL] [Abstract][Full Text] [Related]
18. Study of interleukin-6 production in Alzheimer's disease.
Cojocaru IM; Cojocaru M; Miu G; Sapira V
Rom J Intern Med; 2011; 49(1):55-8. PubMed ID: 22026253
[TBL] [Abstract][Full Text] [Related]
19. Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines.
Reale M; Iarlori C; Gambi F; Feliciani C; Salone A; Toma L; DeLuca G; Salvatore M; Conti P; Gambi D
J Neuroimmunol; 2004 Mar; 148(1-2):162-71. PubMed ID: 14975597
[TBL] [Abstract][Full Text] [Related]
20. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
